



ANNUAL RESULTS 2013

STAR CONFERENCE March 26th, 2014

Company Presentation



Disclaimer

Certain statements in this slide show, including those addressing the Company's beliefs, plans, objectives, estimates or expectations of possible future results or events, are forward-looking statements. Forward-looking statements involve known or unknown risks, including general economic and business conditions, and conditions in the industry we operate and may be affected should our assumptions turn out to be inaccurate. Consequently, no forward-looking statement can be guaranteed and actual future results, performance, or achievements may vary materially from those expressed or implied by such forward-looking statements. The Company undertakes no obligation about the contents nor to update the forward-looking statements to reflect events or circumstances that may arise after the date hereof.







- 2. LASER SOURCES AND SYSTEMS
- 3. THE GLOBAL LASER MARKET
- 4. EL.EN. GROUP
- 5. 2013 FINANCIAL RESULTS
- **6.** 2014 GUIDANCE
- 7. MULTIPLES & COMPARABLES





Cyno shares sale







Sale of 1,1 mln of Cynosure shares


Shares sold: 1,1 mln @ \$ 29,15 net price

Proceeds: \$ 32 mln -> € 23 mln

Gain on sale: € 4,5 mln



Cynosure: the investment history



Residual shares 1 mln
Current price \$ 29





Lasers sources and systems





LASER

Light Amplification Stimulated by Emission of Radiation

MEDICAL LASER Systems






INDUSTRIAL LASER Systems




MEDICAL applications





MEDICAL applications






INDUSTRIAL applications










INDUSTRIAL applications






CONSERVATION and restoration

Pompei – Villa dei Misteri





"Essays cleaning of the frescoes of the Villa dei Misteri in Pompei" June 2013, courtesy of Superintendence for Archaeological Heritage of Naples and Pompei




The Global Laser Market





The MEDICAL Laser Market





The INDUSTRIAL Laser Market

Laser Sources Market

Revenues (\$M)

Source: Industrial Laser Solutions

INDUSTRIAL REVENUE (US\$M)	2012	2013	2014 (F)	
MARKING	\$320.8	\$342.3	\$367.6	
y-to-y		7%	7%	
MICRO MATERIALS PROC.	\$564.2	\$576.7	\$594.5	
y-to-y		2%	3%	
MACRO MATERIALS PROC.	\$1,425.8	\$1,474.4	\$1,541.0	
y-to-y		3%	5%	
TOTAL	\$2,310.8	\$2,393.4	\$2,503.1	
y-to-y		3.6%	4.6%	







El.En. Group







Group Overview

High –Tech laser photonics Group

Develops, manufactures and distributes laser sources and laser systems for medical and industrial applications

Know-how based on 30 years stratification of multidisciplinary experience

December, 31st 2013: Consolidated Revenues of €157 mln, up
4% YoY, 859 employees

Global positioning

Italy	419
Europe	98
China	267
Japan	42
Brazil	31
Other	2



Strategic Strengths

Multidisciplinary and multifacility R&D activity: sources, systems, applications

Covering Medical and Industrial laser markets

Raising technological entry barriers through R&D

Industrial

✓ Combine High tech laser source development with flexible production facilities in high growth areas


Medical

- ✓ Maximize market penetration by multi brand approach
- ✓ Open new market segments by developing innovative applications
- ✓ Leverage worldwide distribution





Consolidated Revenues and EBIT





R&D Activity

Clinical trials and validations of new therapeutic laser treatments and research on new applications of laser- tissue interaction

Raising Technological / Clinical entry barriers

Central role of PHOTOBIOLAB

Medical Aesthetic new multi-application platforms

Vascular lesions systems: VASQ (Dye), Yellow Star Pro

Clinical studies on Mona Lisa Touch

Clinical studies on cutaneous ulcers

Compact RF power sources with increased power

Patents development



Medical/Aesthetic

Aesthetic

Hair Removal

Vascular Lesions

Skin Rejuvenation

Pigmented Lesions

Treatment of Cellulite

Acne

Tattoo Removal

Anti - Aging

LaserBody Sculpting

Removal of Unwanted Fat













Medical

Gynaechology

Endovascular

Dermatology

Psoriasis and Vitiligo

Dentistry

Therapy

General Surgery

Urology

ENT





2013 Financial Results







Consolidated P&L

	Euro /000	31/12/12		31/12/13		Var.%
				unaudited		
	Revenues	151.234	100,0%	157.380	100,0%	4,1%
	Gross margin	72.050	47,6%	74.563	47,4%	3,5%
	EBITDA	12.519	8,3%	13.741	8,7%	9,8%
	EBIT	7.474	4,9%	9.582	6,1%	28,2%
Inco	ome before taxes	6.092	4,0%	10.694	6,8%	75,5%
Income from cont	inuing operations	3.140	2,1%	6.419	4,1%	104,4%
	Net income	23.199	15,3%	6.080	3,9%	-73,8%
Net Incor	me from continuing					
or	perations per share	0,44		1,27		185,5%



Consolidated BS

Euro /00	31/12/12	31/12/13 unaudited	Var.%
Total non current assets (*	62.982	72.976	16%
Net working capita	52.218	48.414	-7%
Net financial positio	n 17.794	21.820	23%
Long term liabilitie	s 9.040	8.904	-2%
Net Equit	y 123.954	134.306	8%
Net capital employe	d 106.160	112.486	6%

(*) Cyno shares value adjustments effect: € 8,7mln



El.En. – Revenues breakdown by business




■ Industrial

Cutting
Marking
Laser sources

Service

Medical Industrial

Medical
Aesthetic
Surgical CO₂
Physiotherapy
Dental





Dec. 31st, 2012

Dec. 31st, 2013

2013: +4%










2014 Guidance











Improvement in EBIT







Multiples & Comparables





El.En. multiples

Stockholder's Equity per share * 27

Price / Book Value Adj. 0,86

EV /EBIT (85% EBIT) 5,84

EV / Sales (85% Sales) 0,36

El.En. Market Cap. 113,4 @ €23,5

Net financial position 21,8 @ 31/12/13

Market value of 2,1 mm Cynosure shares 44,0 @ \$29,15 (Euro/Usd=1,39)

Enterprise Value 48

Stockholder's Equity net of minorities, 131,7

* (with Cynosure shares at market value)



El.En. Comparables

Medical/Aesthetic	Price	Revenue	Var.% Revenue	EBIT	EBIT %	МК.Сар.	EV	EV/Sales	EV/EBIT	P/Book Value
Syneron	\$11,85	\$256.915	-3%	\$(6.119)	-2%	\$419.099	\$336.130	1,31	n.a.	1,81
Zeltiq	\$18,43	\$111.626	32%	\$(19.348)	-17%	\$671.239	\$614.828	5,51	n.a.	10,73
Lumenis	\$11,90	\$265.356	7%	\$25.613	10%	\$419.310	\$446.016	1,68	17,41	23,69
Cutera	\$11,15	\$74.594	-3%	\$(5.256)	-7%	\$157.460	\$74.387	1,00	n.a.	1,87
Biolase	\$2,64	\$56.430	-2%	\$(10.996)	-19%	\$91.009	\$90.103	1,60	n.a.	7,72
Cynosure	\$29,15	\$226.010	47%	\$(5.827)	-3%	\$659.745	\$554.700	2,45	n.a.	2,01
IPG Photonics Co.	\$69,25	\$648.034	15%	\$218.147	34%	\$3.578.840	\$3.133.360	4,84	14,36	3,86
Rofin-Sinar	\$24,01	\$539.024	2%	\$39.526	7%	\$677.226	\$532.664	0,99	13,48	1,22
Prima Industrie	€13,37	€335.841	-4%	€18.681	6%	€137.558	€232.636	0,69	12,45	1,31
El.En. (1)	€23,50	€157.380	4%	€9.582	6%	€113.373	€47.542	0,36	5,84	0,86

⁽¹⁾ EV and multiplies as for previous slide





El.En. SPA

Enrico ROMAGNOLI

Investor Relations Manager

tel. +39 055-8826807

E-mail: finance@elen.it

POLYTEMS HIR SRL

Bianca FERSINI MASTELLONI

Financial Communication

Tel. +39 06-6797849 / +39 06-69923324

E-mail: b.fersini@polytemshir.it

POLYTEMS HIR SRL

Veronica ADRIANI

Press office

Tel. +39 06-6797849 / +39 06-69923324

E-mail: v.adriani@polytemshir.it